<rdf:RDF xmlns:api="http://www.elsevier.com/xml/svapi/rdf/dtd/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33750720650"><dc:identifier>https://api.elsevier.com/content/abstract/eid/2-s2.0-33750720650</dc:identifier><api:scopusId>33750720650</api:scopusId><api:eid>2-s2.0-33750720650</api:eid><api:pubmedId>17083771</api:pubmedId><api:pui>44696876</api:pui><dc:title>Assessing remission in systemic lupus erythematosus</dc:title><prism:issn>0392856X</prism:issn><prism:contentType>Abstract</prism:contentType><prism:aggregationType>Journal</prism:aggregationType><api:srctype>j</api:srctype><api:subtype>ar</api:subtype><api:subtypeDescription>Article</api:subtypeDescription><api:citedbyCount>33</api:citedbyCount><prism:publicationName>Clinical and Experimental Rheumatology</prism:publicationName><api:sourceId>19186</api:sourceId><prism:volume>24</prism:volume><prism:issueIdentifier>6 SUPPL. 43</prism:issueIdentifier><prism:coverDate>2006-11-01</prism:coverDate><prism:copyrightYear>2006</prism:copyrightYear><dc:creator><rdf:Seq><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7006720974"><api:authid>7006720974</api:authid><api:surname>Mosca</api:surname><api:givenName>Marta</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60028868"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7006270830"><api:authid>7006270830</api:authid><api:surname>Bombardieri</api:surname><api:givenName>Stefano</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60028868"/></api:Author></rdf:li></rdf:Seq></dc:creator><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2403"/><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2745"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0032926068"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0032932448"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/2942748316"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33644811656"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/10044261111"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/25444439493"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0034060583"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0036842109"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0035089618"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/4243120895"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0037738674"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/8444226779"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0028582176"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33644813588"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0036673864"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0037331980"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/28444437000"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/4444300345"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0031886296"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0242524630"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0025900754"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0032752441"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/30144435479"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/24344491492"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/22844439577"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0022578857"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0026767866"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0029901773"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0032416213"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/32844466113"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33645037689"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0042694721"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/18644363912"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0033883546"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/1542299615"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/22244485004"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/29944447720"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/2642553217"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0033035577"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/30844446256"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/10444231093"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/17644391456"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/24944588883"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/27444443572"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/4944234742"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33644790320"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33644804877"/><prism:keyword>Activity</prism:keyword><prism:keyword>Damage</prism:keyword><prism:keyword>Quality of life</prism:keyword><prism:keyword>Remission</prism:keyword><prism:keyword>Systemic lupus erythematous</prism:keyword><api:scopusPage rdf:resource="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=33750720650&amp;origin=inward"/></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60028868"><api:afid>60028868</api:afid><skos:prefLabel>Universita di Pisa</skos:prefLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2403"><api:code>2403</api:code><api:abbrev>IMMU</api:abbrev><skos:prefLabel>Immunology</skos:prefLabel><skos:altLabel>Immunology and Microbiology</skos:altLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2745"><api:code>2745</api:code><api:abbrev>MEDI</api:abbrev><skos:prefLabel>Rheumatology</skos:prefLabel><skos:altLabel>Medicine</skos:altLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0032926068"><api:scopusId>0032926068</api:scopusId><dc:title>Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>26</prism:volume><prism:startingPage>504</prism:startingPage><prism:endingPage>507</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0032932448"><api:scopusId>0032932448</api:scopusId><dc:title>Outcome measures to be used in clinical trials in systemic lupus erythematosus</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>26</prism:volume><prism:startingPage>490</prism:startingPage><prism:endingPage>497</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/2942748316"><api:scopusId>2942748316</api:scopusId><dc:title>Clinical trial design in systemic lupus erythematosus: Lessons learned and future directions</dc:title><prism:publicationName>Lupus</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>13</prism:volume><prism:startingPage>406</prism:startingPage><prism:endingPage>411</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33644811656"><api:scopusId>33644811656</api:scopusId><dc:title>OMERACT: An international initiative to improve outcome measurement in rheumatology</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>23</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/10044261111"><api:scopusId>10044261111</api:scopusId><dc:title>Defining response in systemic lupus erythematosus: A study by the systemic lupus international collaborating clinics group</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>31</prism:volume><prism:startingPage>2390</prism:startingPage><prism:endingPage>2394</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/25444439493"><api:scopusId>25444439493</api:scopusId><dc:title>The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>52</prism:volume><prism:startingPage>2854</prism:startingPage><prism:endingPage>2864</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0034060583"><api:scopusId>0034060583</api:scopusId><dc:title>Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2000</prism:publicationYear><prism:volume>27</prism:volume><prism:startingPage>675</prism:startingPage><prism:endingPage>679</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0036842109"><api:scopusId>0036842109</api:scopusId><dc:title>Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients' or physicians' evaluations of recent lupus activity</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2002</prism:publicationYear><prism:volume>29</prism:volume><prism:startingPage>2350</prism:startingPage><prism:endingPage>2358</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0035089618"><api:scopusId>0035089618</api:scopusId><dc:title>The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2001</prism:publicationYear><prism:volume>28</prism:volume><prism:startingPage>525</prism:startingPage><prism:endingPage>532</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/4243120895"><api:scopusId>4243120895</api:scopusId><dc:title>Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus - A 5-yr prospective study</dc:title><prism:publicationName>Rheumatology (Oxford)</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>43</prism:volume><prism:startingPage>1039</prism:startingPage><prism:endingPage>1044</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0037738674"><api:scopusId>0037738674</api:scopusId><dc:title>Design, quality and bias in randomized controlled trials of systemic lupus erythematosus</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2003</prism:publicationYear><prism:volume>30</prism:volume><prism:startingPage>979</prism:startingPage><prism:endingPage>984</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/8444226779"><api:scopusId>8444226779</api:scopusId><dc:title>The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>50</prism:volume><prism:startingPage>3418</prism:startingPage><prism:endingPage>3426</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0028582176"><api:scopusId>0028582176</api:scopusId><dc:title>Serologically active clinically quiescent systemic lupus erythematosus - Predictors of clinical flares</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>1994</prism:publicationYear><prism:volume>1</prism:volume><prism:startingPage>2239</prism:startingPage><prism:endingPage>2241</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33644813588"><api:scopusId>33644813588</api:scopusId><dc:title>Assessment of systemic lupus erythematosus</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>23</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0036673864"><api:scopusId>0036673864</api:scopusId><dc:title>Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randmized trial of low-dose versus high-dose intravenous cyclophosphamide</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2002</prism:publicationYear><prism:volume>46</prism:volume><prism:startingPage>2121</prism:startingPage><prism:endingPage>2131</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0037331980"><api:scopusId>0037331980</api:scopusId><dc:title>LJP394 for the prevention of renal flare in patients with systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2003</prism:publicationYear><prism:volume>48</prism:volume><prism:startingPage>442</prism:startingPage><prism:endingPage>454</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/28444437000"><api:scopusId>28444437000</api:scopusId><dc:title>Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis</dc:title><prism:publicationName>Nephrology</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>10</prism:volume><prism:startingPage>504</prism:startingPage><prism:endingPage>510</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/4444300345"><api:scopusId>4444300345</api:scopusId><dc:title>Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>50</prism:volume><prism:startingPage>2858</prism:startingPage><prism:endingPage>2868</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0031886296"><api:scopusId>0031886296</api:scopusId><dc:title>The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: A decision aid for development of entry criteria for clinical trials</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>1998</prism:publicationYear><prism:volume>25</prism:volume><prism:startingPage>277</prism:startingPage><prism:endingPage>284</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0242524630"><api:scopusId>0242524630</api:scopusId><dc:title>Definition and treatment of lupus flares measured by the BILAG index</dc:title><prism:publicationName>Rheumatology (Oxford)</prism:publicationName><prism:publicationYear>2003</prism:publicationYear><prism:volume>42</prism:volume><prism:startingPage>1372</prism:startingPage><prism:endingPage>1379</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0025900754"><api:scopusId>0025900754</api:scopusId><dc:title>Definition, incidence and clinical description of flare in systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>1991</prism:publicationYear><prism:volume>8</prism:volume><prism:startingPage>937</prism:startingPage><prism:endingPage>944</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0032752441"><api:scopusId>0032752441</api:scopusId><dc:title>Classification and definition of major flares in SLE clinical trials</dc:title><prism:publicationName>Lupus</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>8</prism:volume><prism:startingPage>685</prism:startingPage><prism:endingPage>691</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/30144435479"><api:scopusId>30144435479</api:scopusId><dc:title>Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>33</prism:volume><prism:startingPage>57</prism:startingPage><prism:endingPage>60</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/24344491492"><api:scopusId>24344491492</api:scopusId><dc:title>Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices</dc:title><prism:publicationName>Best Pract Res Clin Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>19</prism:volume><prism:startingPage>685</prism:startingPage><prism:endingPage>708</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/22844439577"><api:scopusId>22844439577</api:scopusId><dc:title>BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus</dc:title><prism:publicationName>Rheumatology (Oxford)</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>44</prism:volume><prism:startingPage>902</prism:startingPage><prism:endingPage>906</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0022578857"><api:scopusId>0022578857</api:scopusId><dc:title>Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs</dc:title><prism:publicationName>N Engl J Med</prism:publicationName><prism:publicationYear>1986</prism:publicationYear><prism:volume>314</prism:volume><prism:startingPage>614</prism:startingPage><prism:endingPage>619</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0026767866"><api:scopusId>0026767866</api:scopusId><dc:title>Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis</dc:title><prism:publicationName>Lancet</prism:publicationName><prism:publicationYear>1992</prism:publicationYear><prism:volume>340</prism:volume><prism:startingPage>741</prism:startingPage><prism:endingPage>745</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0029901773"><api:scopusId>0029901773</api:scopusId><dc:title>"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis</dc:title><prism:publicationName>Kidney Int</prism:publicationName><prism:publicationYear>1996</prism:publicationYear><prism:volume>50</prism:volume><prism:startingPage>2047</prism:startingPage><prism:endingPage>2053</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0032416213"><api:scopusId>0032416213</api:scopusId><dc:title>Outcome criteria for lupus nephritis trials: A critical overview</dc:title><prism:publicationName>Lupus</prism:publicationName><prism:publicationYear>1998</prism:publicationYear><prism:volume>7</prism:volume><prism:startingPage>622</prism:startingPage><prism:endingPage>629</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/32844466113"><api:scopusId>32844466113</api:scopusId><dc:title>The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus</dc:title><prism:publicationName>J Invest Dermatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>125</prism:volume><prism:startingPage>889</prism:startingPage><prism:endingPage>894</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33645037689"><api:scopusId>33645037689</api:scopusId><dc:title>Skin involvement and outcome measures in systemic autoimmune diseases</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>24</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0042694721"><api:scopusId>0042694721</api:scopusId><dc:title>Accrual of organ damage over time in patients with systemic lupus erythematosus</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2003</prism:publicationYear><prism:volume>30</prism:volume><prism:startingPage>1955</prism:startingPage><prism:endingPage>1959</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/18644363912"><api:scopusId>18644363912</api:scopusId><dc:title>Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>52</prism:volume><prism:startingPage>1473</prism:startingPage><prism:endingPage>1480</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0033883546"><api:scopusId>0033883546</api:scopusId><dc:title>Damage in systemic lupus erythematosus and its association with corticosteroids</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2000</prism:publicationYear><prism:volume>43</prism:volume><prism:startingPage>1801</prism:startingPage><prism:endingPage>1808</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/1542299615"><api:scopusId>1542299615</api:scopusId><dc:title>Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations</dc:title><prism:publicationName>Rheumatology (Oxford)</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>43</prism:volume><prism:startingPage>358</prism:startingPage><prism:endingPage>363</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/22244485004"><api:scopusId>22244485004</api:scopusId><dc:title>Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>32</prism:volume><prism:startingPage>1261</prism:startingPage><prism:endingPage>1266</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/29944447720"><api:scopusId>29944447720</api:scopusId><dc:title>Quality of life in rheumatoid arthritis: Impact of disability and lifetime depressive spectrum symptomatology</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>23</prism:volume><prism:startingPage>783</prism:startingPage><prism:endingPage>788</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/2642553217"><api:scopusId>2642553217</api:scopusId><dc:title>Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course</dc:title><prism:publicationName>Arthritis Rheum</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>3</prism:volume><prism:startingPage>465</prism:startingPage><prism:endingPage>474</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0033035577"><api:scopusId>0033035577</api:scopusId><dc:title>Factors associated with fatigue in patients with systemic lupus erythematosus</dc:title><prism:publicationName>Ann Rheum Dis</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:volume>58</prism:volume><prism:startingPage>379</prism:startingPage><prism:endingPage>381</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/30844446256"><api:scopusId>30844446256</api:scopusId><dc:title>Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus</dc:title><prism:publicationName>Autoimmunity</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>7</prism:volume><prism:startingPage>531</prism:startingPage><prism:endingPage>540</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/10444231093"><api:scopusId>10444231093</api:scopusId><dc:title>Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants</dc:title><prism:publicationName>Rheumatology (Oxford)</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>43</prism:volume><prism:startingPage>1580</prism:startingPage><prism:endingPage>1586</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/17644391456"><api:scopusId>17644391456</api:scopusId><dc:title>Relationship of quality of life and physical function in children with systemic lupus erythematosus</dc:title><prism:publicationName>Lupus</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>14</prism:volume><prism:startingPage>280</prism:startingPage><prism:endingPage>287</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/24944588883"><api:scopusId>24944588883</api:scopusId><dc:title>The systemic lupus erythematosus tri-nation study: Longitudinal changes in physical and mental well being</dc:title><prism:publicationName>Rheumatology (Oxford)</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>44</prism:volume><prism:startingPage>751</prism:startingPage><prism:endingPage>755</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/27444443572"><api:scopusId>27444443572</api:scopusId><dc:title>Improvement of coping abilities in patients with systemic lupus erythematosus: A prospective study</dc:title><prism:publicationName>Ann Rheum Dis</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>64</prism:volume><prism:startingPage>1618</prism:startingPage><prism:endingPage>1623</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/4944234742"><api:scopusId>4944234742</api:scopusId><dc:title>Relative versus absolute goals of therapies for RA: ACR20 or ACR50 responses versus target values for "near remission" of DAS or single measures</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>22</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33644790320"><api:scopusId>33644790320</api:scopusId><dc:title>The disease activity score and the EULAR response criteria</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>23</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33644804877"><api:scopusId>33644804877</api:scopusId><dc:title>The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>23</prism:volume></rdf:Description></rdf:RDF>